Second Sight Medical Products Inc (EYES) Given $5.00 Consensus Target Price by Analysts

Shares of Second Sight Medical Products Inc (NASDAQ:EYES) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus target price of $5.00 for the company and are expecting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also given Second Sight Medical Products an industry rank of 161 out of 265 based on the ratings given to its competitors.

A number of research firms recently commented on EYES. Zacks Investment Research raised shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. HC Wainwright set a $5.00 price objective on shares of Second Sight Medical Products and gave the stock a “buy” rating in a report on Tuesday, October 17th.

Second Sight Medical Products (NASDAQ EYES) traded up $0.14 during mid-day trading on Friday, reaching $2.05. 1,480,000 shares of the company were exchanged, compared to its average volume of 395,652. The stock has a market capitalization of $124.99, a P/E ratio of -3.06 and a beta of 3.45. Second Sight Medical Products has a 52-week low of $0.90 and a 52-week high of $2.83.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings data on Thursday, November 2nd. The medical device company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The firm had revenue of $1.61 million for the quarter, compared to the consensus estimate of $1.54 million. Second Sight Medical Products had a negative net margin of 565.12% and a negative return on equity of 184.87%. analysts predict that Second Sight Medical Products will post -0.55 EPS for the current year.

An institutional investor recently raised its position in Second Sight Medical Products stock. Vanguard Group Inc. increased its position in Second Sight Medical Products Inc (NASDAQ:EYES) by 0.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 843,462 shares of the medical device company’s stock after buying an additional 5,973 shares during the period. Vanguard Group Inc. owned about 1.50% of Second Sight Medical Products worth $1,062,000 as of its most recent SEC filing. 12.70% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Second Sight Medical Products Inc (EYES) Given $5.00 Consensus Target Price by Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/03/second-sight-medical-products-inc-eyes-given-5-00-consensus-target-price-by-analysts.html.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Get a free copy of the Zacks research report on Second Sight Medical Products (EYES)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply